透明细胞肾细胞癌的分子特征揭示上皮-间质转化基因表达特征的预后意义
该研究回顾性分析两个ccRCC发现队列,并在TCGA队列(n=386)中验证,发现CCP高/EMT高风险组与最差的PFS和DSS相关(均p<0.001),多变量分析中CCP高/EMT高独立关联于不良PFS和DSS(风险比分别为4.6和10.3,p<0.001)。
要点
- 在发现队列中,瘤栓较原发肿瘤及复发患者较无复发患者均过表达WT1和CCP基因。
- TCGA验证队列中高WT1表达患者富集EMT和CCP相关通路。
- CCP高/EMT高风险组与最差PFS和DSS相关(均p<0.001),多变量分析独立关联(HR=4.6和10.3,p<0.001)。
核心结论
- 研究证明EMT在高CCP评分肿瘤中具有协同预后影响,新型EMT评分有潜力改善风险分层并提供潜在新治疗靶点。
研究设计与样本
- 回顾性识别两个ccRCC发现队列:队列1为根治性肾切除加下腔静脉瘤栓切除术患者(患者=5,样本=24);队列2为局限性病变行根治性肾切除后复发与无复发患者(n=36)。
- 使用TCGA中局限性ccRCC(M0)患者(n=386)进行验证。
- 对两个发现队列的靶向RNA二代测序数据进行差异表达基因分析,在TCGA验证队列中使用Kaplan-Meier生存分析和多变量Cox比例风险检验。
主要发现
- 发现队列中,瘤栓较原发肿瘤及复发患者较无复发患者均过表达WT1和CCP基因。
- TCGA验证队列中,高WT1表达患者的标志性通路分析显示EMT和CCP相关通路富集。
- 在验证队列中衍生CCP和EMT评分,使用Youden指数切点分为四组:CCP低/EMT低、CCP低/EMT高、CCP高/EMT低、CCP高/EMT高。
- CCP高/EMT高风险组与最差PFS和DSS相关(均p<0.001)。
- 多变量分析中,CCP高/EMT高独立关联于不良PFS和DSS(风险比=4.6和10.3,p<0.001)。
关键数值与推荐
- 使用Youden指数切点将验证队列分为四组:CCP低/EMT低、CCP低/EMT高、CCP高/EMT低、CCP高/EMT高。
- CCP高/EMT高组与最差PFS和DSS相关(均p<0.001)。
- 多变量分析中CCP高/EMT高独立关联于不良PFS和DSS(风险比=4.6和10.3,p<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is an ongoing need to develop prognostic biomarkers to improve the management of clear cell renal cell carcinoma (ccRCC). OBJECTIVE: To leverage enriched pathways in ccRCC to improve risk-stratification. DESIGN, SETTING, AND PARTICIPANTS: We retrospectively identified two complementary discovery cohorts of patients with ccRCC who underwent (1) radical nephrectomy (RNx) with inferior vena cava tumor thrombectomy (patients = 5, samples = 24) and (2) RNx for localized disease and developed recurrence versus no recurrence (n = 36). Patients with localized ccRCC (M0) in The Cancer Genome Atlas (TCGA, n = 386) were used for validation. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: A differential expression gene (DEG) analysis was performed on targeted RNA next-generation sequencing data from both discovery cohorts. Using TCGA for validation, Kaplan-Meier survival analysis and multivariable Cox proportional hazard testing were utilized to investigate the prognostic impact of DEGs, cell cycle proliferation (CCP), and a novel epithelial-mesenchymal transition (EMT) score on progression-free (PFS) and disease-specific (DSS) survival. RESULTS AND LIMITATIONS: In the discovery cohorts, we observed overexpression of WT1 and CCP genes in the tumor thrombus versus the primary tumor, as well as in patients with recurrence versus those without recurrence. A hallmark pathway analysis demonstrated enrichment of the EMT- and CCP-related pathways in patients with high WT1 expression in the TCGA (validation) ccRCC cohort. CCP and EMT scores were derived in the validation cohort, which was stratified into four risk groups using Youden Index cut points: CCPlow/EMTlow, CCPlow/EMThigh, CCPhigh/EMTlow, and CCPhigh/EMThigh. The CCPhigh/EMThigh risk group was associated with the worst PFS and DSS (both p < 0.001). In a multivariable analysis, CCPhigh/EMThigh was independently associated with poor PFS and DSS (hazard ratio = 4.6 and 10.3, respectively; p < 0.001). CONCLUSIONS: We demonstrate the synergistic prognostic impact of EMT in tumors with a high CCP score. Our novel EMT score has the potential to improve risk stratification and provide potential novel therapeutic targets. PATIENT SUMMARY: Genes involved in epithelial-mesenchymal transition provides important prognostic information for patients with clear cell renal cell carcinoma.
引用
- Nallandhighal S, Vince R, Karim R, et al. Molecular Characterization of Clear Cell Renal Cell Carcinoma Reveals Prognostic Significance of Epithelial-mesenchymal Transition Gene Expression Signature. Eur Urol Oncol. 2021. PMID: 34840106. doi:10.1016/j.euo.2021.10.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。